AbCellera Biologics (NASDAQ:ABCL) Releases Earnings Results, Beats Expectations By $0.02 EPS

AbCellera Biologics (NASDAQ:ABCL – Get Free Report) issued its quarterly earnings data on Tuesday. The company reported ($0.13) EPS for the quarter, topping the consensus estimate of ($0.15) by $0.02, Briefing.com reports. The company had revenue of $7.30 million during the quarter, compared to analyst estimates of $10.12 million. AbCellera Biologics had a negative return […]

Leave a Reply

Your email address will not be published.

Previous post Hamas has a new leader. How will that affect the war in Gaza and cease-fire efforts?
Next post BMO Capital Markets Trims Lyft (NASDAQ:LYFT) Target Price to $13.00